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Abstract 
An increasing number of people are prescribed blood thinning drugs as oral vitamin K antagonists 
(VKA). The drug is prescribed both prophylactic and therapeutically to a large group of patients at 
increased risk of thromboembolism. Optimal treatment with coumarins (i.e. warfarin) has been 
reported difficult mainly due to high inter- and intraindividual variability between patients’ 
response to the required maintenance dose. Also dietary interaction from food containing vitamin K 
adds to difficulties in treatment with VKA, as vitamin K has an opposing effect of warfarin. 
Research has shown how involvement of patients in their VKA treatment improves the quality of 
the treatment; this is especially the case when patients are allowed to adjust medicine intake based 
upon International Normalized Ratio (INR). The treament is a balance between avoiding adverse 
events as hemorrhages due to over-treatment and thromboembolisms due to under-treatment. The 
quality of the treatment may be further increased by introducing predictive models. Such models 
should account for variance in INR values and be abl to aid patients in optimal dosing of warfarin 
by keeping the INR value at therapeutic level. 
This PhD-project aims to develop predictive models that are able to account for inter- and 
intraindividual variability in patients’ response to warfarin treatment. Furthermore, it has been 
hypothesized that including dietary information on vitamin K intake will increase precision of INR 
predictions. A novel compartment model of vitamin K has been developed and integrated into an 
already described model, which is able to predict INR values based upon warfarin intake. This 
study gave rise to exploration of other predictive factors that could potentially explain variations i 
INR values. Simple statistical techniques were applied to data from orally anticoagulated patients, 
and it was shown how temporal analysis of warfarin intake and vitamin K intake aid in explaining 
variance in INR values. The novel vitamin K model from the first study was refined in a third study 
to further investigate the importance of vitamin K when predicting INR values. A seemingly more 
accurate physiological model of vitamin K dynamics llustrated how vitamin K intake above or 
equal to recommended daily intake explains a large p oportion of the INR prediction error. A fourth 
study was conducted with an attempt to develop a statistical model able to predict INR as well as 
predict a theoretical correct dose of warfarin intake to keep INR values at target level. In a fifth 
study, an analysis concerning variance in INR was conducted to explore the intrapatient variability 
in INR values. By comparing periods with equal intake of warfarin and vitamin K, and applying 
straightforward algebraic manipulation, measured INR values can be used in calculation of the 
intrapatient variability. This value can be regarded as a theoretical minimum of the prediction error 
when applying predictive models to this data. 
All five studies contribute to the understanding of factors affecting variations in INR values. The 
thesis provides indication on the importance of including dietary vitamin K information in optimal 
oral VKA treatment. Further assessment of the proposed models should include trials to assess 
clinical outcome in patients treated with VKA in anout-patient setting. 
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Danish summary/Dansk resumé 
Et stigende antal personer bliver ordineret blodfortyndende medicin så som peroral vitamin K 
antagonister (VKA). Medicinen ordineres både profylaktisk og terapeutisk til en stor gruppe af 
patienter med forhøjet risiko for embolisme. Optimal behandling med coumarin (f.eks. warfarin) 
har vist sig kompleks hovedsageligt grundet høj inter- og intraindividuel variation mellem 
patienternes respons til en givet vedligeholdelsesdosi . Interaktion med fødevarer, som indeholder 
vitamin K, har vist sig at tilføje til udfordringerne i behandling med VKA, da vitamin K har en 
modsatrettet effekt af warfarin. Forskning har vist, a  kvaliteten af behandlingen øges, hvis 
patienterne tager aktiv del i behandlingen. Dette gælder især, når patienterne gives lov til at ændre 
medicinindtaget på baggrund af International Normalized Ratio (INR) værdier. Behandlingen er en 
balance mellem at undgå utilsigtede hændelser som indre blødninger grundet overbehandling, og at 
undgå thrombo-embolismer grundet utilstrækkelig behandling. Kvaliteten af behandlingen kan 
måske øges ved brug af prædiktive modeller. Sådanne modeller skal tage højde for varians i INR 
værdier og skal kunne hjælpe patienter i optimal dosering af warfarin; dette skal hjælpe til at holde 
INR værdierne i terapeutisk interval. 
Dette ph.d. projekt har til formål at udvikle prædiktive modeller, som kan tage hensyn til inter- og 
intraindividuel variabilitet i patienternes respons til behandling med warfarin. Yderligere 
hypotiseres det, at ved inddragelse af information om vitamin K indtag, vil præcisionen af INR 
prædiktionerne øges. En kompartment model af vitamin K er blevet udviklet, og er integreret i en 
allerede beskrevet model, som kan forudsige INR værdier på baggrund af warfarin indtag. Denne 
undersøgelse gav anledning til en udforskning af andre prædiktive faktorer, som potentielt kunne 
forklare varians i INR værdier. Simple statistiske teknikker blev anvendt på data fra peroralt 
antikoagulerede patienter. Det blev vist hvordan analyse af den tidslige anskuelse af warfarin indtag 
og vitamin K indtag hjælper på forklaring af varians i INR værdier. For at få øget indsigt i 
vigtigheden af vitamin K når INR værdier prædikteres, blev modellen af vitamin K fra det første 
studie videreudviklet i et trejde studie. En tilsyneladende mere fysiologisk korrekt model af 
dynamikken for vitamin K viste hvordan vitamin K indtag, i niveau med dagligt anbefalet indtag, er 
istand til at forklare en stor andel af unøjagtigheden i INR prædiktionerne. Et fjerde studie blev 
udført i et forsøg på at udvikle en statistisk model, som kan forudsige såvel INR værdier og 
forudsige et teoretisk korrekt warfarin indtag, forat holde INR værdien i et terapeutisk niveau. I det 
femte studie blev der fortaget en analyse omhandlende varians i INR værdier for at udforske 
intrapatient variabiliteten. Ved sammeligning af perioder med ens indtag af warfarin og vitamin K, 
blev der, ved algebraisk manipulation, anvendt INR værdier i beregningen af intrapatient 
variabiliteten. Værdien fra denne beregning kan anses for at være et teoretisk minimum i 
prædiktionsfejlen, som fås ved anvendelsen af prædiktive modeller på disse data. 
Alle fem studier bidrager til forståelse af faktorer, som kan relateres til variationer i INR værdier. 
Denne afhandling giver indikationer, af hvor vigtig vitamin K er, i optimal behandling med VKA. 
Yderligere vurderinger af de foreslåede modeller bør inkludere forsøg, som er struktureret til at 
vurdere de kliniske resultater ved brug af modellerne til patienter i VKA-behandling. 
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Preface 
This PhD-thesis presents the research and work doneuring my study period, August 2007 to 
August 2010. My affiliation during the PhD-study was the Medical Informatics Group, Department 
of Health Science and Technology, Aalborg University, Denmark. The title of the thesis is 
Modelling in Oral Anticoagulation Treatment. 
The thesis is structured in three main sections: Introduction, Studies, and Discussion and 
conclusion. The Introduction section provides a general introduction to the field of oral 
anticoagulation treatment. Emphasis in this section is on what challenges are involved in the 
treatment and what approaches aim to counter these challenges. Furthermore, a short introduction to 
each of the five studies is given after stating the subject of the thesis. The Studies section presents 
the five studies that constitute this thesis. Each paper is presented in its original form, either as 
submitted or accepted paper. The Discussion and conclusion section gives a discussion of the 
presented work and how the different studies are related. Furthermore, the limitations of the work 
are discussed along with suggested future directions f r research within this field; finally, a brief 
conclusion is given.  
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1. Introduction 
Persons with an increased risk of thrombosis are in need of anticoagulation treatment. The medicine 
used is often a vitamin K antagonist (VKA) that extends the time it takes for the blood to clot, 
thereby reducing the risk of thrombosis. Oral anticoagulation treatment (OAT) has been used in a 
broad medical field with various underlying conditions for more than 60 years. The relation 
between blood clotting and coumarin derivates was established by Dam and Doisy who shared the 
Nobel Prize in 1943 for their work.[1,2] Their main discoveries were the postulation and prove of 
the existence of vitamin K (K for German Koagulation) and the description of structure of the 
vitamin. The fundamental physiological mechanism of affecting synthesis of certain coagulation 
factors was known, however, the biochemical description and understanding was yet to be 
established in the mid 70’ies.[3,4] As of today in Denmark more than 100.000[5] people are taking 
VKA, and in the United Kingdom the number is nearly one million people.[6]  
1.1 Underlying conditions for OAT 
OAT is a prophylaxis treatment commenced to prevent embolisms. Thromboembolisms can occur if 
an embolism is carried in the blood stream, from the site of formation of the clot, into the 
pulmonary artery or one of the main branches. Underlying clinical conditions increasing risk of 
unintended blood clotting in the blood stream can roughly be categorized into these main areas: 
Prosthetic heart valves, atria fibrillation, reduction of the risk of recurrent myocardial infarction, 
and deep venous thrombosis (DVT).  
Thromboembolism remains a serious complication after h art valve replacement whether the 
prosthesis is a mechanical valve or a valve of bioprosthetic tissue. Relatively intensive 
anticoagulant treatment is recommended with mechanial valve replacement, and therapy is 
depending on valve type and position.[7] Bioprosthees do not always require OAT, but patients are 
often anticoagulated for a period of 3-6 months, and with less intensity compared to treatment of 
patients with mechanical heart valve replacement.[8,9] Atria fibrillation is one of the relatively new 
major patient groups who receive OAT to prevent formation of clots due to abnormal blood flow 
caused by the fibrillation.[10] Acute myocardial infarction and treatment with anticoagulants have 
been discussed since introduction of the treatment for this clinical condition. The prophylaxis 
treatment of this is often combined with aspirin.[11] Optimum treatment of DVT with OAT 
requires assessment of whether the thrombosis is proximal or distal. Further, it is important to know 
if the DVT is unprovoked (idiopathic).[12] Other are s where OAT is applied are post-surgery, e.g. 
knee or hip replacement, and hereditary diseases such as thrombophilia. 
1.2 Physiology involved in OAT 
Warfarin is the most widely used coumarin derivative, and throughout this thesis OAT and warfarin 
treatment will be used as synonyms.  
Warfarin 
Warfarin is a racemic mixture of two enantiomers: R-warfarin and S-warfarin, where the latter has 
been reported to have a 2-4 fold increased anticoagulant effect compared to R-warfarin.[13] Both 
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enantiomers are metabolized through the cytochrome P450 (CYP) enzyme group. S-warfarin is 
mainly affected by CYP2C9 while R-warfarin is metabolized through five sub-CYPs.[14] The drug 
is highly bound to albumin in the plasma and has a bio vailability close to 100%.[15,16] The drug 
acts by interfering with the vitamin K cycle, see Figure 1. 
 
Figure 1: A diagram of the actions involved in the vitamin K cycle. Vitamin K is reduced either by a NADH dependent 
reductase activity, reaction ‹1›, or a reductase reaction dependent on the conversion of dithiol into disulfide, ‹3› 
(shaded). The carboxylation reaction, ‹2›, which converts glutamate residues (Glu) into gamma-carboxyglutamate 
residues (Gla), is driven by a vitamin hydroquinone (KH2) dependent carboxylase activity. This activity simultaneously 
converts vitamin KH2 into vitamin K epoxide. The last step in the vitamin K cycle, reaction ‹3›, is a reductase of 
vitamin K epoxide dependent on conversion of dithiol into disulfide. The two reactions indicated by ‹3› are inhibited by 
vitamin K antagonists as warfarin, thus dietary vitamin K sources are necessary to maintain haemostasis. 
 
Warfarin acts by a partly or complete block of two different steps in the vitamin K cycle. When 
vitamin K hydroquinone (VKH2) availability is decreased, the vitamin K-dependent carboxylation 
of glutamic acids is reduced. If this reaction is halted, only limited amount of vitamin K epoxide 
will be available for recycling of vitamin K by the enzyme Vitamin K epoxide reductase complex 
subunit 1 (VKORC1).[17] This leads to synthesis of proteins induced by vitamin K absence, i.e. 
coagulation factors missing a carbon chain and unable to function in the coagulation cascade.[18] 
Synthesis of functional vitamin K dependent coagulation factors now becomes dependent on new 
sources of vitamin K. Coagulation factor II (prothrombin), factor VII (stable factor), factor IX (anti 
haemophilic factor B), and factor X (Stuart-Prower factor) are all vitamin K dependent; besides 
these, protein C, protein S, and protein Z are proteins depending on vitamin K. 
After warfarin treatment has been initiated, the first effects on INR values occur within two or three 
days.[19] Heparin is recommended to be concurrently administered due to the effect from warfarin 
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on all vitamin K depending proteins. Protein C and protein S are inhibiting activated factor VII in 
the coagulation cascade, and have a shorter half-life than most of the vitamin K dependent 
coagulation factors. If heparin is not administered, coagulation factors with longer half-life (relative 
to the regulative anticoagulant proteins C and S) could potentially exert a procoagulation effect. 
Heparin will add the anticoagulation effect needed before the warfarin effect reaches steady-
state.[20] 
Vitamin K 
Two natural forms of vitamin K exists: phylloquinone often referred to as vitamin K1, and 
menaquinones referred to as vitamin K2. A third source of vitamin K is a synthetic precursor of 
vitamin K2, called menadione or simply vitamin K3. Vitamin K1 is mainly found in leafy green 
vegetables, such as spinach, parsley, broccoli and k le.[21] Also beef and pork liver contain high 
amounts of vitamin K due to the fact that these anim ls feed on a diet rich in leafy greens. Internal 
production of vitamin K2 is believed to involve the microflural population in the large intestine, and 
to be an important source of vitamin K.[22] The absorption of vitamin K is thought to be governed 
by the principles of fat-soluble vitamins including the need of bile salts, and appears mainly in the 
upper part of the small bovel.[18,23] The dietary intake of vitamin K is recommended to be 
approximately 1µg per kilogram body weight per day.[24] 
1.3 Challenges involved in OAT 
In spite of the well established evidence for warfarin treatment, under-utilization of the treatment 
has been shown in studies where more than half the eligible patients are not receiving 
treatment.[25,26] One of the main reasons for this is the fear of adverse events such as 
haemorrhagic. The OAT becomes a balance between avoiding the risk of bleeding complications, 
and not under treating the patient, which might lead to thrombotic events.  
International Normalized Ratio 
The quality of OAT is often assessed by measuring the International Normalized Ratio (INR), 
which provides a standard for comparing blood coagulation tests. The INR is calculated based on 
Prothrombin Time (PT) as follows: 
INR = (patient PT / mean normal PT)ISI 
where ISI is an international sensitivity index of the responsiveness of thromboplastin, which is 
used as reactant in the PT measurement. PT is obtained by measuring the time it takes for the blood 
to clot after adding thromboplastin. The recommended INR target value is diagnosis dependent; e.g. 
atria fibrillation has a target INR of 2.5, while mechanic heart valve replacement often requires a 
slight higher target INR of 3.0 or 3.5. Instead of a specific value of the INR target a therapeutic 
window is utilized and regarded as adequate treatment with OAT; e.g. atria fibrillation has a 
therapeutic window of INR between 2 and 3.[8] Furthe  quality assessment of the treatment 
involves calculation of Time (spent) in Therapeutic Range (TTR), which uses consecutive INR 
measurements to establish a percentage based number indicating the duration where INR values are 
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within the preset window.[27] Studies indicate that both in clinical trials and routine settings 
optimizing OAT to increase TTR is still a complicated task.[28,29]  
Flensted and colleagues investigated the variation in consecutive INR values, with an attempt to 
eliminate external sources of variation (vitamin K intake, drug interactions, alcohol consumption, 
etc.).[30-32] One of the main research goals was to quantify random fluctuations in INR 
measurements. Fluctuations could be due to “spontaneous variation” or reflect clinical relevant 
change in coagulation. If random fluctuations were accounted for between two consecutive INR 
measurements, the difference between these measurements could be of sub-clinical interest. They 
proposed a novel method that quantifies critical difference between two INR measurements. A 
retrospective test of this method revealed a “ping-pong” effect, where changes in dose of coumarin 
were made based on INR measurements outside therapeutic window, but without critical difference 
compared to the last measurement; this causes oscillating INR values. Further elaboration of their 
model lead to quantification of critical difference on the INR scale taking INR target into 
consideration: with target INR at 2.5 the differenc between two measurements of clinical interest is 
0.7, and for target INR at 3.5, the clinical critical difference is 1. In summary, the work from 
Flensted and colleagues indirectly proved the fact tha there is a lack of a simple relationship 
between a dose of VKA and the therapeutic effect.  
Genetic variations 
Mutations in the gene coding for warfarin metabolism enzymes have been shown to alter the 
response to warfarin treatment, thus increasing inter-i dividual INR variation. Some of the best 
documented wild types of CYP2C9*1 is CYP2C9*2 and CYP2C9*3.[33] These mutations are 
associated with an impaired ability to metabolize warfarin, hence prolonging warfarin half-life and 
leading to reduced warfarin requirements. Screening for gene-mutations before initiating warfarin 
treatment is an ongoing discussion, but the relation between the mutations and higher risk of 
bleeding has been established.[34,35]  The VKORC1 enzyme is the target for warfarin’s inhibitory 
effect on the vitamin K cycle. Mutations in this gene have shown to account for some of the 
difficulties to maintain INR at target level.[36] Whereas of three well-described wild types of 
CYP2C9, there is a higher degree of diversity in mutations on VKOR1C; some leads to warfarin 
resistance, while others lead to reduced VKOR activity.[37] Fifty percent of the inter-individual 
variation on warfarin response is believed to be dir ctly accounted for by the pharmacokinetic 
variants (CYP2C9) and pharmacodynamic variants (VKORC1).[38,39] A population based model 
of different types of genetic mutations and warfarin treatment showed the effect of different 
combination of wild type alleles. The model showed how equal dose of warfarin could potential 
lead to an INR value of 2 in one patient, and an INR value above 6 in another patient solely 
depending on gene mutations.[40] 
Dietary vitamin K 
OAT can be affected by numerous environmental factors hat can alter warfarin kinetics and 
dynamics.[41] Vitamin K dietary intake is one of these factors, which may alter the response to 
warfarin treatment. New external sources of vitamin K will increase the production of functional 
coagulation factors depending on vitamin K. The clini al relevance of changes in vitamin K has 
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been discussed, and it has been shown how patients with poor dietary intake of vitamin K often has 
less stable control of anticoagulation.[42] It has been suggested to provide these unstable 
anticoagulated patients with oral vitamin K supplementation; however unrecognized intake of such 
can lead to warfarin resistance.[43] Other studies reported that steady-state warfarin treatment was 
not affected by dietary vitamin K intake.[44,45] However, Khan and colleagues suggested that their 
findings, of vitamin K having no effect in their regression model, could be related to the fact that 
warfarin dosage had already been adjusted to control for individual vitamin K status. Further, they 
only involved patients whose dose of warfarin remained constant. Variations in vitamin K might be 
greater in patients who do not receive an optimized warfarin dose that remains constant. Although 
Loebstein and colleagues reported vitamin K as negligible; a recently published review by the same 
research group acknowledges that vitamin K plays an important role in maintaining therapeutic 
stability.[46] The magnitude of clinically relevant change in dietary vitamin K intake has been 
reported to be above 100µg/day.[47-50] A prospective study established proof f the clinical 
relevance of vitamin K as a major independent factor that interferes with OAT stability [51], and de 
Assis and colleagues established a dietary vitamin K strategy to improve OAT.[52]  This approach 
has, however, been questioned, and suggested to be most effective for those who are under-
anticoagulated and only consume small amounts of vitamin K rich foods.[53] Still, it remains clear 
that patients who have poorly controlled OAT will benefit from a diet with controlled vitamin K 
content.[54] 
1.4 Approaches to counter challenges in OAT 
Approaches to improve OAT include (among others) development of new antithrombotic drugs, use 
of different types of management of the treatment, a d use of computer software that can aid in 
dose adjustment. 
Through the last decade researchers have been working on development of a new type of 
antithrombotic drug, which could eliminate or minimize the difficulties in warfarin treatment: the 
relatively narrow therapeutic window, large inter-individual dose response, drug-to-drug 
interactions, and the need for close monitoring that is ssociated with the fear of adverse events of 
over-treatment. Direct thrombin inhibitors are a newly developed class of anticoagulants that acts 
by directly inhibiting activated clotting factor II. Another type of newly developed drug class is 
direct clotting factor X inhibitors.[55,56] Both drug classes can be given in a fixed dose and does 
not require routine monitoring. Large-scale randomized controlled trials have been conducted with 
different types of commercially available analogues, and the usage has been explored in different 
clinical conditions.[57-64] A discussion of whether or not these new drugs will completely replace 
the use of warfarin is beyond the scope of this theis. However, the topic is an ongoing discussion 
in the literature.[65-68]  
Types of OAT management 
In general three different types of OAT management exist.[69] One is “routine-care” where patients 
visit the hospital-based anticoagulation clinic or General Practitioner (GP) every 4-6 weeks to have 
the INR value measured. Some patients can take part in the management of OAT by handling a 
coagulometer as a Point-of-Care device and measure INR values themselves. Patients assigned to 
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“self-testing” (PST) will report this INR value to a responsible clinician who decides on dosage 
adjustment of warfarin. Patients educated in “self-management” (PSM) will both handle INR 
measurement, and are allowed within a preset range to change warfarin dosage. In the latter two 
groups, measurements of INR values are most frequent: once every week or two.  
Studies have compared how well OAT is controlled when the treatment is managed by the primary 
physician and when the treatment is managed by a specialized anticoagulant management service: 
Compared to routine-care managed by the GP, management handled by the specialized clinic was 
shown to reduces complication rates for more than 50% of the cases, and achieves higher 
TTR.[70,71] A large randomized controlled trial comparing specialized anticoagulant management 
service and treatment by the GP did, however, fail to show a significant difference in TTR between 
the two types of management.[72]  
PST and PSM are recommended as effective alternative treatment models compared to routine-care. 
Heneghan and colleagues conducted a meta-analysis and pooled estimates from 14 randomized 
controlled trials of PST.[73] They reported significant lower rate of thrombotic events and lower 
mortality in PSM compared to PST. However, this type of management was noted not to be suited 
for every patient, and patients should be carefully identified and educated in PSM.[26,74,75]  
Decision support systems 
Computer programs with algorithms capable of predicting the next warfarin dose (or response to a 
future warfarin dose), can potentially aid poorly controlled dose management in OAT. Such 
systems are based on different approaches ranging from strict expert-based algorithms, population-
based pharmacokinetic/pharmacodynamic (PK/PD) models, and rigid mathematical methods such 
as regression modelling. Bayesian parameter optimization methods are common techniques in the 
latter two approaches, and are meant to account for inter- and intraindividual response to VKA.[76]  
Through the past 25 years computerized decision support systems (CDSS) have been available to 
assist clinicians in OAT. Some of the first studies have shown that such systems can be at least as 
effective as experienced physicians with regard to dose adjustment.[77-79] In a large scale 
multicenter randomized trial Poller and colleagues showed the effective use of the computer 
program DAWN AC.[80] The computer program gave signif cantly better INR control compared to 
physician management. Another approach by Manotti and colleagues using the software program 
PARMA (later PARMA 5) achieved similar results as the DAWN AC study; even though they 
obtained a slight higher TTR.[81,82] Poller and colleagues conducted yet another multicentre 
randomized study comparing the use of DAWN AC and PARMA 5 in different countries.[83] This 
proved that computer-assisted dosage could be both safe and effective. However, the American 
College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) do not 
directly recommend use of CDSS, and the guidelines state that it should be based on physician 
preferences.[13] 
Modelling in OAT 
The CDSS used in OAT could be based on PK/PD models that account for warfarin metabolism 
and warfarin’s effect on vitamin K dependent coagultion factors. Such models can be useful for 
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estimating inaccessible pharmacodynamic parameters, which may be useful in determining the 
pharmacological action on each individual coagulation factor. An excellent review in the field of 
modelling in OAT has been published by N.H.G. Holford.[84] His review and the work by L. B. 
Sheiner have partly set the stage for PK/PD models veloped throughout the years in the field of 
OAT.[85] One of their important contributions was the link between levels of clotting factor and PT 
or INR, which was established by a theoretical compund referred to as Prothrombine Complex 
Activity (PCA). This made it possible to link the fairly accurate kinetics of warfarin and the 
coagulation factors with the clinical tests, and hence made it possible to develop models that could 
be used in a clinical setting. Ovesen and colleagues conducted a small study including 35 patients, 
and showed that using techniques for predicting warfarin dose was significantly better than 
empirically dosing.[86] 
Some of the very early CDSS were only sporadically tested, but the result from modelling 
physiology involved in OAT was promising.[87] Abbrecht and colleagues developed a model that is 
able to predict PCA. It was retrospectively evaluated and marked as a good representation of the 
involved physiological system. Prospective evaluation of the model proved a slightly worse 
performance in terms of days to reach therapeutic PCA intervals when compared to the control 
group.[88] Wiegman & Vossepoel described the use of a compartment modelling to develop a dose-
response model of warfarin, which was able to predict coagulation time. At that time it was 
successfully used for the majority of the patients i  a Dutch specialized anticoagulant management 
service.[89] Svec and colleagues published a PK/PD model using a Bayesian forecasting technique 
to predict the prothrombin ratio based on population based parameters. By adapting these 
parameters by feedback from five prothrombin ratio measurements, they almost doubled the 
accuracy of the predictions giving a Root Mean Square (RMS) error of 0.219.[90] Boyle and 
colleagues achieved a prediction error of the same lev l as Svec and colleagues, using a Bayesian 
regression model (named WarfCalc), and also required f v  measurements to achieve the reported 
results.[91] A large variety of models, with different modelling approaches for predicting warfarin 
treatment, have been described and evaluated.[92-105]  
Vadher and colleagues developed a compartment model that is able to predict warfarin dosage 
based on INR predictions; this approach was evaluated in a randomised controlled trial with 148 
patients requiring initiation of warfarin treatment.[106,107] The model is comprised of four 
compartment models that handles coagulation factor II, VII and X, and plasma warfarin. The INR 
value is calculated based on a fraction of the mentioned coagulation factor, which (in modelling 
context) is not affected by warfarin intake. The model was incorporated into a CDSS and proved to 
lower the median time to achieve a stable dose of war arin (7 days), compared to trainee doctors 
(9days).  
Pasterkamp and colleagues developed a simplified moel (named TRODIS) based on the structure 
proposed by Holford.[108] The model calculates a maintenance dose of warfarin, based on an 
individual sensitivity parameter, to keep a patient o  INR target. The proposed dosages from the 
model were initially evaluated by two “dosing experts” in three levels: in 91.8% of the cases (of 194 
proposals) they were ranked as “good”. A more solid evaluation of the model was conducted in a 
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double-blinded, randomized controlled trial in 712 patients where a new algorithm (named ICAD) 
was introduced. The ICAD algorithm allowed for continuous adjustment of the sensitivity 
parameter over time, and proved to be significantly better than the original TRODIS model.[109]  
2. Aim of PhD-thesis 
The focus of this PhD-thesis is an assessment of the effect of predictive factors than can influence 
INR values. From the previous chapter, it is evident that such factor is dietary vitamin K, which 
however, has not been utilized in a modelling context. The objective of the work presented in this 
thesis is therefore to explore the usage of vitamin K in modelling in OAT and to reveal the 
magnitude of the effect from vitamin K on INR values, in order to explain some of the variation in 
INR values.  
2.1 Studies employed in the PhD-thesis 
The first novel attempt, of using vitamin K in a model predicting INR values, was based on the 
model described and tested by Vadher and colleagues.[107] Their model has been expanded with a 
one-compartment model, which handles both pharmacokinetic and pharmacodynamic aspects of 
vitamin K from dietary intake. The model is able to predict INR values seven days into the future, 
and handles patient sensitivity to warfarin individually. This is done by a warfarin sensitivity 
parameter, which is continuously updated each time he model is presented to an INR value. This is 
presented in the paper “Assessing Importance of Dietary Data in Anticoagulation Treatment”. 
Further investigation of factors that potentially could affect INR variations was carried out by using 
simple statistical models. Data sampled with high frequency (once per day) was used to detect local 
(or short-term) variations in consecutive INR measurements. This allows for detection of predictive 
factors affecting INR variations, where time has been taking into consideration. A number of 
univariate linear regression models were employed, an  F-tests were applied to remove models that 
would not benefit in decreasing observed variance on INR values. This study is presented in the 
paper “Data Mining to Assess Variations in Oral Anticoagulation Treatment”. 
Another investigation using the previously described compartment model was performed to 
evaluate the impact of dietary vitamin K intake. Inspired by the results using the statistical 
regression model, the compartment model was slightly refined to account for effects from vitamin 
K during a longer period of time. To further assess the importance of dietary vitamin K, the model 
was evaluated both on data where patients have consumed recommended daily requirement of 
vitamin K and on data where patients consumed vitamin K above this recommendation. This is 
presented in the paper “Model based prediction of INR utilizing vitamin K information”. 
A seemingly very different modelling approach was made to investigate the possibility of not only 
predicting INR values, but also predicting a theoretical correct dose of warfarin to keep an 
individual patient on a specific target INR value. The developed model is set on state-space form 
and is using Kalman filtering technique to update parameters used in the prediction of INR values 
16 
 
and theoretical correct warfarin. The model is presented in the paper “A Dynamic Prediction Model 
for Anticoagulation Therapy”. 
A fifth study was conducted to assess the intrapatient variability in INR values. Intrapatient 
variability can be used to give a theoretical quantifica ion of the lowest achievable prediction error 
for e.g. metabolic models. Matching pairs of shorter p riods of data (three days) with identical 
warfarin intake and vitamin K intake was used to estimate the intrapatient variability in the data 
used throughout the work that comprises this thesis. The analysis is presented in the paper 
“Estimation of Intra-patient Variation in Clinical International Normalized Ratio (INR) Data Used 
to Evaluate a Predictive Model in Oral Anticoagulation Treatment”. 
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3. Studies 
This chapter of the thesis presents the scientific work. Each section corresponds to a study and a 
paper. The papers are provided in the original form, both accepted for publication and submitted for 
publication. Statuses of the papers of September 2010 are: 
• Assessing Importance of Dietary Data in Anticoagulation Treatment: Published in Studies 
in Health Technology and Informatics 
• Data Mining to Assess Variations in Oral Anticoagulation Treatment: Accepted for 
publication on MEDINFO 2010 – 13th World Congress on Medical and Health Informatics 
• Model based prediction of INR utilizing vitamin K information: Submitted to Journal of 
Thrombosis and Haemostasis 
• A Dynamic Prediction Model for Anticoagulation Therapy: Submitted to Computer 
Methods and Programs in Biomedicine 
• Estimation of Intrapatient Variation in Clinical International Normalized Ratio (INR) Data 
Used to Evaluate a Predictive Model in Oral Anticoagul tion Treatment: Submitted to 
Clinical Chemistry 
Each of the papers will in the following sections have its individual list of reference in the end of 
the publication. 
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4. Discussion and conclusion 
For more than 50 years VKA has been prescribed in prophylactic and therapeutic treatment to 
people with an increased risk of thrombosis.[6,13] The main physiological process involved in OAT 
with warfarin is the vitamin K cycle.[16] Warfarin interferes with two different steps in the 
biochemical process of recycling vitamin K.[17,19] If vitamin K supplies are halted, the liver 
cannot produce functional vitamin K dependent clotting factors. This leads to impaired haemostasis 
and the time it takes for the blood to form a clot is prolonged. Vitamin K is found in different types 
of food, e.g. leafy green vegetables.[21] If adequate amounts of vitamin K are consumed by patients 
in warfarin treatment, this will mediate changes in INR values as new sources of vitamin K are 
available to the liver.[46,47,50] Optimal treatment wi h warfarin has been shown difficult due to 
inter- and intraindividual response to the treatment.[31,40] One of the main causes of this is related 
to the variation in enzyme alleles leading to differences in the metabolism of warfarin and recycling 
of vitamin K.[31,39,40] Patients assigned to PSM have shown to benefit from this type of 
management.[110] Some of these patients use CDSS that can aid them in warfarin dosing to keep 
their INR value at target level. Large randomized controlled clinical trials have shown how the use 
of CDSS can lead to higher TTR when compared to conventional management.[81-83] The models 
used in CDSS in OAT have been refined through the past 25 years.[111] A large proportion of these 
systems are based on PK/PD models that are modelling the physiology related to the 
treatment.[84,89,90] Two studies have evaluated two different models used to provide initial and 
maintenance doses of warfarin. It was shown how the results using the models were comparable to 
the results in the control groups where trainee doctors were giving dosage advice.[106,109] 
The work described in this thesis investigates the use of different modelling approaches to examine 
factors affecting variation in INR values. The thesis further aims to add to the knowledge regarding 
the relevance of using dietary information on vitamin K when predicting INR values. 
In the first study, a novel model of the impact of dietary vitamin K on INR values was proposed. 
The model was based on the model of Vadher and colleagues [107], which was evaluated in 
warfarin initiation. Even though our model can be used to predict warfarin initiation dose and 
maintenance dose, this was not tested in the study as the scope was to assess the importance of 
vitamin K when predicting INR values. The model was evaluated on data from five patients in OAT 
assigned to PSM. The study indicated a potential benefit from including vitamin K when predicting 
INR values. However due to the limited number of patients, the strength of vitamin K as a predictor 
of INR values remained unclear from this study. Furthermore, other factors of potential importance 
were not considered. 
In the second study, a wider approach to assess potential parameters that explain INR variation was 
taken. Of special interest were temporal relations between warfarin and vitamin K intake and INR 
measurements. Data from 18 patients in OAT were used to evaluate a set of different univariate 
linear regression models. Due to warfarin pharmacokinetic parameters (with a half-life of 
approximately 36 hours) it was chosen to include four days of past intake in the study to explain 
INR variation; the same period was chosen for past vitamin K intake. Therefore, the initial 
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regression model included INR values and warfarin and vitamin K intake from the past four days 
(i.e. all 3 types of data from day -4 to -1). This model was then successively reduced by using F-test 
statistics to determine whether or not each parameter contributed in explaining INR variation (at 
day zero). The final model for predicting INR on day zero used the following input: INR from day -
1 (lag 1 INR); deviation in warfarin intake on day -1 relative to the mean warfarin intake in the past 
4 days; deviation in vitamin K intake on day -2 relative to the mean vitamin K intake in the past 4 
days.  
In the third study, the physiological model (developed in the first study) was refined in accordance 
with the results from the second study. A data set was divided into a training set used to estimate the 
model parameters, and a test set that was used to evaluate the INR predictions from the model. The 
results showed how the average INR prediction error can be significantly reduced by using a model 
including vitamin K information. Not surprisingly, the effect of including vitamin K information 
was found to be largest in data containing relatively large vitamin K consumption (on or above 
recommended daily requirements).  
In the fourth study, a quite different type of prediction model was developed; a state space model 
using an extended Kalman filter to optimize parameters each time the model was presented to a new 
INR value. The algorithm takes warfarin intake and INR measurements as input, and based on 
these, the model performs INR predictions and suggests a theoretical correct dose of warfarin to 
maintain an individual target INR. When no INR measurements are available as input, the model 
expands the confidence limits of the INR prediction. 
A fifth study was conducted in order to assess intrapatient variability in INR values. In data from 18
patients in warfarin treatment, matching pairs of shorter periods of data, with identical warfarin 
intake and vitamin K intake, were identified. Under the assumption of independence between the 
two periods in a pair, the pair of INR values on the last day in the two periods was used to calculate 
the intrapatient variability. The study illustrated how the intrapatient variability can be compared 
with the RMS prediction error when using a model to predict INR values. 
4.1 Comparison of the models 
The presented studies of modelling in OAT are based on data from the same data collection 
protocol. This provides an opportunity to compare th  outcome of each study. Table 1 summarizes 
the results comparing the average Root Mean Square (RMS) error of the predicted INR values for 
the three models when predicting one day into the future. 
Study Without 
warfarin  
information 
With warfarin 
and vitamin K 
information 
Number of patients in the test 
Model 1 (section 3.1) 0.235 0.210 5 
Model 3 (section 3.3) 0.264 0.291 13 
Model 4 (section 3.4) 0.266 Not available 18 
Table 1: Summary of the predictive performance of the three predictive models expressed as average Root Mean Square 
INR prediction errors. 
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The size of the data material varies between the three studies, which adds to the difficulties when 
comparing the RMS errors. Furthermore, the number of measurements used to adjust the models is 
different: for example Model 1 uses five INR measurements to estimate the warfarin sensitivity 
(warfsens) before making the predictions. Model 4 does initially only use one INR measurement to 
produce predictions, and therefore the initial confidence limits of the INR prediction are wide, as 
the parameters are not (yet) adapted to each individual. As more measurements are added the 
quality increases. In the study on Model 4, all 18 patients are used both for developing the model 
and for testing the model, whereas in the study on M del 3, the first 5 patients are used to develop 
the model and the remaining 13 patients are used to tes  it. Even though this theoretically might 
favour the test results for Model 4, the consequences of the differences in test design are expected to 
be very small. It can be argued from Table 1 that te models perform equally well when predicting 
INR values a single day into the future. 
Adding vitamin K information reduces one day prediction RMS errors in Model 1 but increases the 
error in Model 3. It should be noted, though, that for predictions 7 days into the future, both Model 
1 and Model 3 have a lower prediction error when including vitamin K information. The effect of 
adding dietary vitamin K information to Model 4 still remains to be assessed. Model 4, in its current 
form, generates a suggested dose of warfarin and predicts INR for the following day. Model 1 and 
Model 3 are not limited to an INR prediction once a day: the implemented compartment models 
generate a prediction of INR values each hour. Even though the performance of Model 1 and Model 
3 is only evaluated against measured INR values once a day, visual inspection of the INR 
predictions between INR measurements appear to be in accordance with the expected physiological 
behaviour. Figure 2 shows the level of each of the t ree modelled coagulation factors in a 
simulation during the warfarin initiation phase. 
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Figure 2: A simulation of the development of three coagulation factors during the initiation of warfarin treatment using 
Model 3. The concentration in the warfarin compartment is illustrated by the green area (using an arbitr ry scale); the 
daily intake of warfarin being in the range of 2.5mg to 5mg (corresponding to the vertical steps of the green area). The 
three curves, depicting each coagulation factor, are showing the proportion of each of the functional coagulation factors 
in the model. From the slope and shape of the curves, th  importance of the half-life of each of the factors becomes 
evident. Factor VII has a relatively short half-life (3-6 hours), while Factor II has a relatively long half-life (60 hours). 
The proportions of functional coagulation factors are the basis for the INR calculation in Model 1 and 3. 
 
The proportion of functional coagulation factors in warfarin treatment illustrated in Figure 2 is in 
accordance with other studies.[112,113] Even though Model 4 might also have been implemented 
allowing for e.g. hourly INR predictions, it was, however, chosen not to attempt to model 
physiology. One could argue that how this model behav s between INR measurements is - in a 
strict sense - not interesting for this particular type of model. 
Model 4 has the ability to directly provide a suggested warfarin dose to keep the INR value at 
target. This functionality could also be added to Mdel 1 and Model 3 by implementing an iterative 
algorithm suggesting the optimal warfarin dose: the dose that by using the model is predicted to 
lead to the best possible future INR values. Doing this, Model 1 and Model 3 could be used as an 
inference engine in a decision support tool for warfarin dosage adjustment. The warfarin adjustment 
can also be done manually illustrating the expected INR values after changes suggested by patients 
or clinicians. 
As described in the fifth paper, the data used through ut the thesis have an intrapatient variability of 
0.46 if warfarin is considered as the dominant external source of variation, and an intrapatient 
variability of 0.36 if both warfarin and vitamin K intake are included in the calculation. Under the 
assumption of independence in the calculation, the intrapatient variability is the theoretical minimum 
for the RMS prediction error and it can therefore be used as a benchmark. It can be seen that the 
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average RMS error for the one day predictions, listed in Table 1, are all significantly lower than the
intrapatient variability. This can be explained by a relatively high correlation between data from two
consecutive days. In fact, the results described in the fifth paper seem to indicate that INR 
measurements are not independent for a period of at leas  3-4 days. This is however, in good 
accordance with action profiles for warfarin and vitamin K: For example if the warfarin intake, which 
usually is taken in the morning by a particular patient, is shifted to the evening, this will not only 
influence the next day’s INR measurements but will have an effect on several days of INR 
measurement. Likewise, a vitamin K rich meal will influence INR measurements for more than one 
day. Other unknown factors may contribute to the correlation between consecutive days: changes in 
warfarin sensitivity, exercise, alcohol intake etc. At present, only Model 1 and 3 can predict more than 
one day into the future. The difference between the intrapatient variability and the RMS prediction 
error of Model 1 and Model 3 after 7 days seems to be around 0.1. This indicates that the model 
prediction error for these models is close to the theoretical minimum.  
4.2 Limitations 
The data used in all the studies were collected based upon a standardized diary for daily collection 
of OAT data. The content of vitamin K in the diet was not accurately measured, but was estimated 
based upon diet notes in the diary. From the notes, the “USDA National Nutrient Database for 
Standard Reference edition 16”[114] was used to estimate vitamin K in the diet. This method may 
introduce a bias. The patients estimated the amount of each type of food, and wrote notes like “half 
a plate of salad”. From this type of information it is not possible to obtain the exact amount of 
vitamin K in the diet. To counter this, one might request the patients to weigh each type of food in 
each meal, and for example give an accurate description of the type of salad: “80 grams of iceberg 
lettuce”. However, it is believed that this approach would be an extra burden on the patients 
substantially increasing the dropout rate.  
Since the patients enrolled in the data collection measured the INR value once a day, the data 
available in the studies cannot be regarded as repres ntative of “normal” OAT data. If patients were 
not enrolled in this study, a weekly INR measurement would have been recommended to this type 
of patients. A high frequency of INR measurements ha  been shown to increase the time in 
therapeutic range (TTR) and to benefit the quality of the treatment.[7,115] Hence, the data used in 
the studies show well-regulated anticoagulated patients; which is also evident from a high average 
TTR of 81.2%. It is unknown if the proposed prediction models would perform differently if 
presented to a set of data from less well-regulated patients. The studies assessing the quality of the 
models use a retrospective approach, and they have to be followed by proper prospectively designed 
studies to assess the impact on clinical outcome whn using the models to adjust the warfarin 
dosage. 
4.3 Future directions 
Future work should aim to further explore the impact of vitamin K information when predicting 
INR values. Temporal aspects of the physiology could be of interest: what is the duration of the 
effect of a change in vitamin K intake on INR values? Furthermore, what is the threshold of the 
amount of vitamin K intake that can induce a clinically important change in INR values? Such 
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studies could add to the knowledge regarding the usefulness of vitamin K information when 
predicting INR values. An important question to answer is whether patients will benefit from taking 
into account the intake of vitamin K when making decisions on warfarin dosing in OAT. 
Prospective intervention studies should be carried out to assess the causal relation between the 
vitamin K intake and the need for warfarin adjustment in OAT. 
The proposed models should be evaluated on datasets from a broad range of patients in OAT. The 
thesis has illustrated how the models perform when usi g a dataset of high quality in terms of 
frequency of measurements, which only allows for conclusions regarding this type of patients: The 
conclusions cannot be extended to the broad range of patients. This would require a much larger 
dataset including all types of patients. It might terefore, be relevant to perform another 
retrospectively designed study using a large dataset with a broad population of patients in OAT. An 
interesting dataset might be collected from patients that follow the normal treatment pattern of 
patients assigned to PSM who often measure INR approximately once a week. 
To assess whether the proposed models can improve the outcome of OAT, e.g. measured as 
increased TTR, prospective clinical studies should be conducted. This would require further system 
development in order to implement the models in a CDSS to make it possible for clinicians and/or 
patients to operate the models. The study design should be a randomized controlled trial and it 
might include patients assigned to PSM letting the int rvention group use a model based CDSS.  
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4.4 Conclusion 
This PhD thesis describes two quite different predictive modelling approaches in OAT, with and 
without the use of vitamin K information. Evaluation results are compared with an estimate of the 
intrapatient variability.  
Three of the five papers describe the development of models capable of predicting future INR 
values. Two models are using compartment modelling techniques and are using INR values to 
estimate an individual warfarin sensitivity parameter. The third predictive model is based on 
statistical techniques and is able to give a suggestion on a theoretically correct warfarin dose for 
keeping the INR at a designated target. One of the papers in this thesis analyses various factors that 
may explain INR variations. The last paper describes a method for estimating the intrapatient 
variability, which can be used as a benchmark when evaluating the predictive power in predictive 
models. 
Through this dissertation, the relevance of further studies on the temporal relation between vitamin 
K and OAT has been emphasized. Studies assessing the clinical outcome of using the proposed 
predictive models in a decision support system still need to be carried out. 
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